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ABSTRACT 
N-acetylglucosamine (O-GlcNAc) transferase 
(OGT) regulates protein O-GlcNAcylation, an 
essential and dynamic post-translational 
modification. The O-GlcNAc modification is 
present on numerous nuclear and cytosolic 
proteins and has been implicated in essential 
cellular functions such as signalling and gene 
expression. Accordingly, altered levels of protein 
O-GlcNAcylation have been associated with 
developmental defects and neurodegeneration. 
However, mutations in the OGT gene have not 
yet been functionally confirmed in humans. 
Here, we report on two hemizygous mutations in 
OGT in individuals with X-linked intellectual 
disability (XLID) and dysmorphic features: one 
missense mutation (p.Arg284Pro) and one 
mutation leading to a splicing defect (c.463-
6T>G). Both mutations reside in the 
tetratricopeptide repeats of OGT that are 
essential for substrate recognition. We observed 
slightly reduced levels of OGT protein, and 
reduced levels of its opposing enzyme O-
GlcNAcase (OGA) in both patient-derived 
fibroblasts, but global O-GlcNAc levels 
appeared to be unaffected. Our data suggested 
that mutant cells attempt to maintain global O-
GlcNAcylation by downregulating OGA 
expression. We also found that the c.463-6T>G 
mutation leads to aberrant mRNA splicing, but 
no stable truncated protein was detected in the 
corresponding patient-derived fibroblasts. 
Recombinant OGT bearing the p.Arg284Pro 
mutation was prone to unfolding and exhibited 
reduced glycosylation activity against complex 
array of glycosylation substrates and proteolytic 
processing of the transcription factor host cell 
factor 1 (HCF1), which is also encoded by an 
XLID-associated gene. We conclude that defects 
in O-GlcNAc homeostasis and HCF1 proteolysis 
may play roles in mediation of XLID in 
individuals with OGT mutations.   
 
 
Protein O-GlcNAcylation is a dynamic and 
reversible post-translational modification that is 
present on many nucleocytoplasmic and 
mitochondrial proteins (1,2). O-GlcNAcylation 
involves cycling of a single N-acetylglucosamine 
(O-GlcNAc) moiety on serine and threonine 
residues of a spectrum of substrates, affecting 
their stability, activity and subcellular 
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localization (3,4). The transfer of O-GlcNAc is 
catalysed by O-GlcNAc transferase (OGT) (5,6) 
and is modulated by the availability of the donor 
substrate UDP-GlcNAc (7). UDP-GlcNAc 
biosynthesis is coupled to glucose, glutamine and 
nucleotide metabolism. Concomitantly, OGT 
exerts a nutrient-sensitive regulation over various 
cellular functions by acting on myriad targets 
(8). OGT is highly conserved in metazoa and 
consists of multiple tetratricopeptide repeats 
(TPRs) on the N-terminus and a C-terminal 
glycosyltransferase domain (9,10). While TPRs 
are known to be involved in protein-protein 
interactions, in the context of OGT they facilitate 
substrate recognition and specificity (11). In 
addition to its glycosyltransferase activity, OGT 
was recently shown to have a role in proteolytic 
processing of Host Cell Factor 1 (HCF1) (12,13), 
a transcriptional co-regulator of the cell cycle 
(14). HCF1 is heavily O-GlcNAcylated (15), but 
a recent study revealed that O-GlcNAcylation 
and proteolytic cleavage of HCF1 by OGT are 
independent processes (16). OGT activity is 
counteracted by O-GlcNAcase (OGA), a 
hexosaminidase that specifically removes O-
GlcNAc modifications (17). It has been shown 
that chemical inhibition of OGA in different 
human cell lines leads to a decreased expression 
of OGT and an increased expression of OGA 
(18), which indicates an as yet unidentified 
mechanism of regulation to maintain global O-
GlcNAc homeostasis. OGT has been linked to 
embryonic development in a number of animal 
models. Caenorhabditis elegans with null 
mutations in ogt-1 are viable and fertile, but with 
metabolic defects (19). In Drosophila, OGT is 
encoded by the super sex combs gene, which is 
essential for Drosophila viability and 
segmentation (20,21). Knockdown of OGT in 
zebra fish causes impaired embryonic growth 
with reduced brain size (22). Although OGT is 
ubiquitously expressed, it is remarkably 
abundant in brain (9,10). Accordingly, O-
GlcNAcylation has been linked to neuronal 
function and brain development in a number of 
cell and animal models (23),(22). In addition, 
recent studies have shown that O-GlcNAc 
signalling can regulate axonal and dendritic 
growth (24,25) and AMPA receptor trafficking 
(26,27), possibly affecting learning and memory 
processes. Also, alterations in protein O-
GlcNAcylation have been associated with 
neurodegenerative diseases (28). 
Genetic OGT variants identified in patients with 
X-linked intellectual disability (XLID) have 
previously been documented: firstly, in a clinical 
report, albeit accompanied by mutations in 
MED12 (a known XLID gene) (29) and secondly 
in a large screen for novel XLID genes (30). 
Here, we describe two patients with intellectual 
disability, bearing hemizygous mutations in 
OGT. By combining characterization of the O-
GlcNAcylation machinery in patient cells and 
characterisation of the effects of OGT XLID 
mutations on OGT dual activity in vitro, we 
provide preliminary evidence suggesting that 
effects on the O-GlcNAc proteome and 
proteolytic processing of HCF1 may underpin 
the observed XLID phenotypes. 
 
 
RESULTS  
Clinical phenotype of two ID patients  
Two male patients showed intellectual disability 
and a developmental delay due to an unknown 
cause. 
Cognitive testing in patient 1, at the age 
of 5 years old, showed reduced intelligence 
(WPPSI-III-NL, score 2;9) and delay in adaptive 
behaviour (VABS, score 2;0). Additional 
neurological symptoms were pyramidal 
syndrome, mild spastic diplegia and 
psychomotor retardation with behavioural 
conduct disorder. In addition, patient 1 had an 
inguinal hernia. Dysmorphic features included 
hypertelorism, low set ears, a broad nose, full 
lips, supernumerary nipple, hypoplastic toe, mild 
retrognathia, long and thin fingers, clinodactyly 
and microcephaly (Fig. 1A). Patient 1 showed 
involvement of the eyes including amblyopia and 
possible astigmatism. He was born with a mild 
respiratory insufficiency based upon transient 
tachypnea of the neonate. Cardiac screening 
revealed a bicuspid aortic valve. An MRI at the 
age of 2 years old showed mild abnormalities 
pointing towards periventricular leukomalacia 
(Fig. 1C), but with a normal EEG.  
The global developmental level of 
patient 2, at the age of 5.5 years old, was 
estimated at 1.5 years. He showed mouth 
hypotonia with drooling, and involvement of the 
eyes including nystagmus, astigmatism and high 
hypermetropia. Genital abnormalities included a 
small phallus, and orchiopexy was performed at 
the age of 3 years. His dysmorphic phenotype 
was less evident, with bitemporal narrowing and 
metopic ridge as main features (Fig. 1B). Upon 
birth, a ventricular septal defect was detected, 
which closed spontaneously at later age. An MRI 
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performed at the age of 3 years old showed no 
clear brain abnormalities (Fig. 1D).  
Clinical features of the patients are summarized 
in Table 1. 
 
Identification of mutations in OGT  
Whole exome sequencing was performed in the 
two male patients from unrelated families to 
uncover the cause of their intellectual disability. 
Mutations in OGT were found in both patients.  
In patient 1, trio-sequencing and filtering 
for de novo variants revealed two potential 
candidate genes. A heterozygous de novo 
mutation was found in bromodomain-containing 
protein 1 (BRD1): Chr22(GRCh38):  
g.49,823,630C>G; NM_001304808.1:c.688G>C 
(p.Val230Leu). In addition, a hemizygous de 
novo missense variant in OGT was discovered: 
ChrX(GRCh38): g.71,555,312G>C; 
NM_181672.2: c.851G>C (p.Arg284Pro) (Fig. 
2A). Arg284 is conserved among many 
vertebrates and some invertebrates such as 
Drosophila (Fig. S1). In silico analysis of 
p.Arg284Pro in OGT predicted pathogenicity of 
the mutation (Table 2). The heterozygous nature 
of the mutation in BRD1, in addition to lower 
pathogenicity predictions for p.Val230Leu 
(Table 2) made this variant less likely to be 
pathogenic.  
For patient 2, a gene panel for known 
intellectual disability genes and de novo analysis 
did not reveal a potential causative mutation. 
Further analysis of the exome data by filtering 
for variants following an autosomal recessive or 
X-linked inheritance showed a hemizygous 
variant in OGT: ChrX(GRCh38): 
g.71,544,561T>G; NM_181672.2: c.463-6T>G. 
Segregation analysis revealed that the mutation 
originates from a de novo mutation in the 
grandmother of the patient, passed on via the 
mother, who is the carrier (Fig. 2A). The 
thymine at position c.463-6 is highly conserved 
(phyloP score of 6.93) and in silico splicing 
analysis of c.463-6T>G predicted an effect on 
the canonical splice site. RT-PCR in patient 
fibroblasts showed an additional splice variant  
for OGT (Fig. 2B). Sanger sequencing showed a 
deletion of 69 base pairs, corresponding to 
skipping of exon 4 due to partial loss of the 
canonical splice site in patient 2 (Fig. 2B). 
Skipping of Exon 4 could result in a truncated 
protein with a loss of 23 amino acids (Δ155-177-
OGT).  
Both mutations in OGT were absent in >60.000 
controls (ExAC database) (31).  
Thus, we have identified two XLID patients that 
possess two novel mutations in OGT.  
 
OGT XLID mutations lead to an imbalance of O-
GlcNAc homeostasis  
Given that OGT is a glycosyltransferase we next 
investigated the effects of the XLID mutations 
on global O-GlcNAc levels in lysates from 
patient-derived fibroblasts by immunoblotting. 
As controls, we used fibroblasts from an 
unrelated male neonate (control 1) and a female 
adult (control 2). Using the RL2 anti-O-GlcNAc 
antibody, we observed no substantial difference 
in global O-GlcNAc levels between the controls 
and patients  (Fig. 3A and 3B). To verify the 
specificity of this O-GlcNAc antibody, cell 
lysates were treated with a bacterial O-
GlcNAcase from Clostridium perfringens 
(CpOGA), leading to a loss of O-GlcNAc signal 
compared to untreated lysates (Fig. 3A). As an 
independent control experiment, we applied a 
recently developed method to detect O-
GlcNAcylated proteins, which relies on detection 
using a tagged inactive bacterial O-GlcNAcase 
(Asp298Asn-CpOGA) (32). In this experiment, 
no substantial differences were observed in 
global O-GlcNAc levels in fibroblasts derived 
from patients versus healthy controls (Fig. 3C 
and 3D).  
We next investigated the effects of the 
OGT mutations on levels of OGT and OGA 
mRNA and protein. Gene expression levels of 
OGT and OGA appeared to be unaffected in 
patient fibroblasts compared to those of the 
controls (Fig. 4A). Although OGT protein levels 
appeared reduced in both patients compared to 
the healthy controls (Fig 4B and 4C), there was 
considerable variability in OGT protein levels of 
the healthy controls (Fig. 4B and 4C). At the 
mRNA level two OGT variants (corresponding 
to WT and misspliced products) were present for 
patient 2 (Fig. 2B). However, at the protein level,  
comparative analysis with recombinantly 
expressed Δ155-177-OGT (Fig. 4F) did not show 
evidence for presence of a truncated OGT 
protein, suggesting that Δ155-177-OGT may be 
unstable/degraded in the context of these patient 
fibroblasts. There was a reduction in OGA 
protein levels, although again variability was 
observed in OGA protein levels of the healthy 
controls (Fig. 4D and 4E).  Thus, OGT mutations 
may lead to reduced functional OGT protein 
levels in patient-derived fibroblasts, which may 
be compensated for with downregulation of 
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OGA protein levels, thereby maintaining global 
O-GlcNAc levels. 
 
Recombinant mutant OGT is unstable and 
defective in HCF-1 processing 
The absence of the truncated OGT in patient 2 
and potential reductions in OGT protein levels in 
patient-derived fibroblasts suggest that the 
mutations may compromise OGT stability. To 
further investigate this, stability of recombinant 
wild type/mutant OGT TPR domain was 
analysed by thermal denaturation experiments. 
We observed reduced stability for Δ155-177-
OGT (Tm = 51  1 ˚C) and Arg284Pro-OGT 
(Tm = 52  1 ˚C) compared with wild type OGT 
TPR domain (Tm = 59  1 ˚C) (Fig. 5A). Given 
that Δ155-177-OGT was not detected in patient-
derived fibroblasts, further biochemical 
characterisation of this mutant was omitted. OGT 
has over a thousand O-GlcNAcylation substrates, 
therefore, in order to explore the effects of the 
Arg284Pro mutation in an environment similar 
to that of cell physiology, de-O-GlcNAcylated 
HEK-293 cell lysate was employed as a complex 
array of substrates.  Arg284Pro-OGT was not 
able to restore  protein O-GlcNAcylation,  to the 
extent achieved by wild type OGT (Fig. 5B).  
 OGT is known to possess a second 
catalytic activity, promoting autocatalytic 
cleavage and activation of the transcriptional co-
regulator HCF1, itself an XLID gene (33,34), via 
an intermediate glycosylation step (13,35). Thus, 
we decided to investigate the effects of the 
Arg284Pro mutation on OGT-mediated HCF1 
processing. To measure proteolytic activity, we 
used a GST-fusion of a minimal HCF1 fragment 
(HCF1-rep1) possessing the first of the PRO-
repeats (which are the target sites of proteolysis, 
Fig. 5C). Wild type OGT was able to 
hyperglycosylate HCF1-rep1, as evidenced by a 
band shift that was reversible by incubation with 
CpOGA (Fig. 5D). The HCF1-rep1 band shift 
observed in the Arg284Pro-OGT-catalysed 
reaction was smaller, suggesting that the mutant 
OGT was less effective than the wild type in 
glycosylating HCF1-rep1 (Fig. 5D). 
Furthermore, wild type OGT was able to induce 
auto-proteolysis, whereas the proteolytic activity 
of Arg284Pro-OGT was reduced (Fig. 5D). 
When the enzyme concentration was reduced 
relative to substrate levels, proteolytic activity of 
Arg284Pro-OGT was abrogated, whereas wild 
type enzyme still displayed detectable activity 
(Fig. 5E). Thus, recombinant Arg284Pro-OGT is 
defective in HCF1 glycosylation and proteolytic 
processing. 
 
DISCUSSION 
Here, we report two patients with XLID 
attributable to hemizygous mutations in OGT: 
one missense mutation (Arg284Pro) and one 
splice-site mutation (c.463-6T>G). We identified 
potential perturbations in protein O-GlcNAc 
homeostasis in both patients and altered HCF1 
maturation in patient 1.  
XLID is a genetically and phenotypically 
heterogeneous group of disorders, estimated to 
account for approximately 10% of all intellectual 
disability phenotypes in males (36). Mutations 
causing XLID have been reported in over 100 
genes, and new XLID genes are still being 
identified (37). In 2015, Niranjan et al. published 
a series of 65 potential XLID genes, by 
sequencing the X-exome of 56 XLID families 
(30). This was the first publication in which a 
genetic variant in OGT (p.Leu254Phe) was found 
associated with XLID.  During the course of our 
work, Vaidyanathan et al. (38) reported a study 
on the functional characterisation of this 
previously published p.Leu254Phe variant of 
OGT (30). In patient derived lymphoblastoid 
cells, decreased OGT levels were accompanied 
by decreased OGA levels, resulting in unaltered 
O-GlcNAc levels. This is in agreement with our 
findings in both patient-derived fibroblast cell 
lines, indicating that homeostasis of O-GlcNAc 
levels through decreasing OGA could be a 
general principle in cases of OGT deficiency. 
However in contrast to our results, 
recombinantly expressed p.Leu254Phe OGT and 
wild type OGT showed equal activity towards O-
GlcNAc substrate CK2α and HCF-1 (38). 
Another study described a missense mutation in 
OGT (p.Ala319Thr) in an XLID family, although 
this mutant also segregated with a previously 
uncharacterised variant of MED12, another gene 
that is associated with XLID. Evidence for 
functional loss of OGT for this mutation was not 
provided (29).  
To date, including our findings, four 
hemizygous mutations in OGT have been 
identified in patients with XLID (Table 1). The 
three missense mutations (p.Arg284Pro, 
p.Leu254Phe and p.Ala319Thr) and one splice-
site mutation (c.463-6T>G) all affect the N-
terminal TPR domain (Fig. 2C and S1). The TPR 
motif is characterised by a repeat of 34 amino 
acids that fold into two antiparallel helices. The 
TPR domain consists of 13.5 repeats and the 
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antiparallel helices align to form an elongated 
superhelix, where the first helix of each TPR 
repeat (helix A) faces towards the inner surface 
of the elongated superhelix and their antiparallel 
pairs (helix B) form the outer surface (11). The 
missense mutations p.Arg284Pro, p.Leu254Phe 
and p.Ala319Thr are located in helix B of the 
OGT TPRs7, 8 and 9, respectively (Fig. 2D and 
S1). In addition, Ala319 is one of the conserved 
hydrophobic amino acid residues of the 
canonical TPR repeat (39) (Fig. S1). Each of 
these missense mutations could disrupt the α-
helical secondary structure of the TPR domain, 
thereby affecting the overall stability of the 
elongated superhelix (Fig. 2D). The Arg284 is 
located in the middle of TPR helix 7B, and 
mutation of this residue to a Pro likely disrupts 
this secondary structure element, destabilising 
this region. 
The splice-site mutation c.463-6T>G is 
predicted to result in an OGT protein missing 23 
amino acids (p.Δ155-177) (Fig. 2B), although we 
could not confirm the presence of a truncated 
OGT in patient fibroblasts (Fig. 4F). We propose 
that this mutation might exert its effect by 
producing an unstable splice variant and 
reducing the amount of functional OGT within 
the cell (Fig. 4B and 5A). Global O-GlcNAc 
levels in patient-derived fibroblasts were not 
substantially reduced compared to healthy 
controls (Fig 3).Protein levels of OGT and OGA 
appeared to be reduced in both patients, however 
both healthy controls displayed variation in their 
OGT and OGA levels, complicating the 
interpretation of these findings. We hypothesize 
that the decrease in OGT protein levels in these 
cells might be counteracted by the concomitant 
reduction of OGA protein levels (Fig. 4D and 
4E), thereby sustaining basal O-GlcNAc 
homeostasis. This hypothesis is supported by the 
finding that chemical inhibition of OGA in 
different human cell lines leads to a decreased 
expression of OGT and an increased expression 
of OGA (18), which indicates an as yet 
unidentified mechanism of regulation to maintain 
global O-GlcNAc homeostasis. We propose a 
similar mechanism in our patient-derived 
fibroblasts.  
It is as yet not fully understood how 
OGT recognises serines/threonines on specific 
proteins for O-GlcNAcylation, although there is 
evidence to suggest that the TPRs play a key role 
for at least a subset of substrates (40). To assess 
the in vitro activity of OGT with mutations 
affecting the TPR domain and the impact on 
substrate O-GlcNAcylation, we produced 
recombinant Arg284Pro-OGT. Given that Δ155-
177-OGT was not detected in patient-derived 
fibroblasts, further biochemical characterisation 
of this mutant was not undertaken. Activity 
assays against de-O-GlcNAcylated HEK-293 
lysate demonstrated that the p.Arg284Pro 
mutation led to a global reduction in protein O-
GlcNAcylation, as opposed to reducing 
recognition and O-GlcNAcylation of specific 
substrates. In a physiological context, this non-
specific reduction in OGT activity may be 
rescued by down-regulation of OGA levels, 
which was observed to some extent in the 
fibroblasts from both patients. However, the 
p.Arg284Pro mutation is located on the surface 
of the TPRs (11), a region that has been shown to 
play a role in the recognition of specific 
substrates (40). It is therefore possible that this 
mutation could affect modification of specific 
substrates, in addition to causing the observed 
global reduction in substrate O-GlcNAcylation, 
and this possibility is neither excluded nor 
confirmed by our current data. O-GlcNAcylation 
activity of Arg284Pro-OGT against HCF1-rep1 
was reduced, as judged by the poly-O-
GlcNAcylation-induced shift in HCF1-rep1 
molecular weight versus wild type OGT (Fig. 
5D).    
In addition to being abundantly O-
GlcNAcylated (15), HCF1 is also proteolytically 
processed by OGT (12,35). The  Arg284Pro 
mutation appears to alter HCF1-rep1 proteolysis 
in vitro (Fig. 5D and 5E). The TPR domain is 
critical for proteolytic maturation of HCF1 (13) 
and this could explain why Arg284Pro-OGT 
shows decreased proteolytic activity towards 
HCF1 in vitro. Interestingly, HCFC1, the gene 
that codes for HCF1, is located on the X-
chromosome and it is reported as an XLID gene 
(41). This hints at possible overlap in 
downstream disease mechanisms causing 
intellectual disability in patients bearing OGT or 
HCFC1 mutations. 
Precisely how alterations in protein O-
GlcNAcylation and HCF1 cleavage lead to 
intellectual disability is not yet clear. OGT is 
expressed in a broad range of tissues, with a 
remarkably high expression in brain (9,10). O-
GlcNAc modified proteins were detected in 
nerve terminals and abundant OGT activity was 
detected in nerve synaptosomes (42), indicating 
that O-GlcNAc could play a role in neuronal 
function and neurodegenerative disease. It has 
been suggested that regulation of the proteasome 
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complex by O-GlcNAcylation in the brain could 
contribute to apoptosis of hippocampal cells, and 
thus neurodegeneration (43). In addition, 
aberrant O-GlcNAcylation levels have been 
linked to neurodegenerative diseases like 
Alzheimer’s disease (28). Future work analysing 
the effect of XLID mutations on OGT function 
in a more phenotype-relevant model, such as a 
neuronal cell line or an animal model where the 
effect of the mutations on different tissues, 
including the brain, can be investigated, would 
be important. The present study utilised 
fibroblasts from two unrelated individuals as 
controls, and we noted substantial variability in 
OGA and OGT protein levels in these cells, 
complicating the interpretation of our data. In 
order to minimise the effect of variability 
introduced by the differing genetic background 
between individual patients and controls, it 
would be of use to introduce these mutations into 
cell lines with an identical genetic background. . 
Our study provides the first detailed 
clinical characterisation of patients with XLID 
attributable to mutations in OGT, and 
furthermore, proposes a potential molecular 
explanation for how these mutations may impact 
on OGT dual function of O-GlcNAcylation and 
HCF1 proteolysis. 
 
EXPERIMENTAL PROCEDURES 
 
Patient consent 
Exome sequencing and use of patient facial 
images was done with written informed consent. 
 
Whole exome sequencing 
For patient 1, whole exome sequencing was 
performed in a trio diagnostic approach as 
described before (44). Exome capture was 
performed with the SureSelect Human All Exon 
v4 enrichment kit (Agilent, CA, USA). Whole 
exome sequencing was performed on the 
Illumina HiSeq platform (CA, USA). Data were 
analysed with BWA (read alignment) and GATK 
(variant calling) software packages. Variants 
were annotated using an in-house developed 
pipeline. Prioritization of variants was done by 
an in-house designed ‘variant interface’ and 
manual curation.  
Exomes of patient 2 and parents were enriched 
using the SureSelect XT Human All Exon V5 kit 
(Agilent) and sequenced in rapid run mode on 
the HiSeq2500 sequencing system (Illumina) at a 
mean target depth of 100X. The target is defined 
as all coding exons of UCSC and Ensembl +/- 
20bp intron flanks. At this depth >95% of the 
target is covered at least 15X. Reads were 
aligned to hg19 using BWA (BWA-MEM 
v0.7.5a) and variants were called using the 
GATK haplotype caller (v2.7-2). Detected 
variants were annotated, filtered and prioritized 
using the Bench NGS Lab platform (Cartagenia, 
Agilent). OGT gene sequences of grandmother 
and great-grandmother were analysed to study 
the origin of the mutation. All potentially 
causative variants were confirmed by Sanger 
sequencing. 
 
Cell Culture 
Skin fibroblasts derived from patients and 
healthy donors were cultured at 37 °C under 
5.0% CO2 in M199 medium (PAN biotech, 
Aidenbach, Germany) or Dulbecco's Modified 
Eagle Medium (Thermo Fisher Scientific, MA, 
USA) containing 2 mM L-glutamine (Sigma, 
MO, USA). Media were supplemented with 10% 
Foetal Calf Serum (Labtech, Uckfield, UK) and 
1% Penicillin-Streptomycin (Thermo Fisher 
Scientific).  
 
RNA extraction, cDNA synthesis and (q)RT-PCR 
Total cell RNA was extracted from skin 
fibroblasts using TRIzol reagent (Thermo Fisher 
Scientific). cDNA was synthesized with 
RevertAid First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific) using random 
hexamer primers. For quantification of OGT and 
OGA expression levels, cDNA from skin 
fibroblasts was mixed with GoTaq® qPCR 
Master Mix (Promega, WI, USA) and both 
forward and reverse primers. Tubulin expression 
was used as an internal control. All qPCR 
experiments were conducted at Biorad CFX96 
Real-Time System following the GoTaq® qPCR 
Master Mix manual. Specificity of the reactions 
was verified with melt curve analysis. Primers 
used are listed in table S1. For analysis of OGT 
mRNA splicing in skin fibroblasts of patient 2, 
cDNA and primers were mixed with AmpliTaq 
Gold® 360 Master Mix (Thermo Fisher 
Scientific). RT-PCR was conducted according to 
standard conditions and PCR products were 
purified using QIAquick Gel Extraction Kit 
(Qiagen, Hilden, Germany). Purified PCR 
products were used for sequencing analysis. 
 
Biochemical characterization of patient-derived 
fibroblasts  
Patient-derived fibroblasts were grown on 15 cm 
plates and were washed twice with ice cold PBS 
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buffer (Thermo Fisher Scientific) prior to lysis. 
Cells were lysed by addition of lysis buffer (50 
mM Tris-HCl, pH 7.4, 1 mM EGTA, 1 mM 
EDTA, 1% Triton-X100, 1 mM Na3VO4, 50 mM 
NaF, 5 mM pyrophosphate, 0.27 M sucrose) 
supplemented with 1 µM GlcNAcstatin-G, 1 µM 
ß-mercaptoethanol and protease inhibitor 
cocktail (1 mM benzamidine, 0.2 mM PMSF, 5 
mM leupeptin). The lysate was transferred into 
an Eppendorf and clarified by centrifugation at 
4˚C (1200 g for 15 min). Lysate proteins were 
resolved by SDS-PAGE (4-12% acrylamide 
[Thermo Fisher Scientific]) and transferred onto 
nitrocellulose membranes (GE Healthcare, IL, 
USA). Analysis of O-GlcNAcylated fibroblast 
proteins by the far Western method was 
performed as described previously (32). Briefly, 
soluble cell lysates were prepared, resolved by 
SDS-PAGE (3-8% Tris-acetate [Thermo Fisher 
Scientific] and transferred onto nitrocellulose 
membranes (GE Healthcare) as described above, 
but with lysis buffer lacking GlcNAcstatin-G.  
 
Protein expression and purification  
Full length wild type OGT and mutants 
(Arg284Pro and ∆155-177) were expressed in E. 
coli as N-terminal His fusion proteins as 
described previously (45). The wild type OGT 
TPR domain (residues 16-410) and mutants 
(TPR-Arg284Pro and TPR-∆155-177) were 
expressed and purified as described previously 
(11). HCF1-rep1 (residues 867-1071) was 
expressed in E. coli as a non-cleavable N-
terminal GST and C-terminal His fusion protein. 
Transformed BL21 (DE3) cells were grown, 
induced for expression, lysed and clarified as 
described previously (45). Clarified lysate was 
incubated with 1 ml/L of culture of Glutathione 
Sepharose 4B resin (GE Healthcare) for 2 h at 4 
°C. The resin was thoroughly washed with base 
buffer (0.1 M Tris-HCl, pH 7.5, 150 mM NaCl, 
0.5 mM TCEP) and eluted using base buffer 
supplemented with 0.5 M glutathione. Eluted 
protein was dialyzed overnight at 4 °C in buffer 
A (0.1 M Tris-HCl, pH 7.5, 25 mM NaCl). 
Dialyzed protein was passed through 5 ml 
HiTrap Q Sepharose FF anion exchange resin 
(GE Healthcare), collecting the flow-through, 
which was then concentrated and passed through 
a 300 ml Superdex
TM
 200 column (GE 
Healthcare) pre-equilibrated with base buffer. 
The peak fractions were concentrated to 10 
mg/ml, mixed 1:1 with 50% glycerol, snap-
frozen and stored at -80 ˚C until use.  
 
Molecular cloning  
The fragment of HCF1-rep1 (residues 867-1071) 
was obtained from MVP Human total Brain 
RNA from Agilent using the Takara PrimeScript 
High Fidelity RT-PCR Kit. The reverse primer 
coded for the C-terminal addition of a 6His tag. 
The PCR product was cloned as a BamHI-NotI 
fragment into a mutated version of pGEX6P1 
which lacks the PreScission protease site. The 
full length codon optimised OGT was obtained 
from GenScript and sub cloned as a BamHI-NotI 
fragment into pHEX6P1 (modified version of 
pGEX6P1 which contains a 6His tag instead of 
GST). The Arg284Pro and the Δ155-177 
mutations were introduced using a method 
similar to the QuikChange site-directed 
mutagenesis kit (Agilent) but using KOD 
polymerase and DpnI from Fermentas. All 
inserts were confirmed by DNA sequencing.  
 
Thermal denaturing assay 
Thermal denaturing experiments were performed 
in triplicate, using the OGT TPR domain 
constructs. 50 µl solutions contained 5 µM 
protein and 1.1x SYPRO® Orange dye (Sigma) 
in base buffer of 25 mM HEPES-NaOH pH 7.5, 
150 mM NaCl and 0.5 mM TCEP. A BioRad 
(CFX Connect) Real-Time System was used to 
measure fluorescence (λex = 530 nm, λem = 560 
nm) while temperature was increased from 25 to 
95 ˚C at 1 degree per minute increments. The 
data was transformed, normalised and fitted to a 
Boltzmann sigmoidal curve using GraphPad 
Prism 5.0.  
 
In vitro O-GlcNAcylation assay 
O-GlcNAcylation assays were performed in 
triplicate on de-O-GlcNAcylated HEK-293 
lysate proteins. HEK-293 cell lysates were 
prepared as described for patient-derived 
fibroblasts, but with the lysis buffer lacking 
GlcNAcstatin-G. HEK-293 lysate was treated 
with 120 µg CpOGA per mg of lysate protein 
and incubated for 90 minutes at 37 ˚C. CpOGA 
was neutralised by addition of 250 µM 
GlcNAcstatin-G. Reactions were supplemented 
with wild type OGT or Arg284Pro-OGT (0.2 
µM) in presence of 2 mM UDP-GlcNAc and 
incubated for an additional 2 h at 37 ˚C. Proteins 
were resolved by SDS-PAGE (3-8% acrylamide 
[Thermo Fisher Scientific]) and transferred onto 
nitrocellulose membrane (GE Healthcare).  
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In vitro proteolytic assay 
Proteolytic assays were performed using HCF1-
rep1 (residues 867-1071) with GST and His tags 
at the N-terminus and C-terminus, respectively. 
For qualitative measurement of proteolytic 
activity, HCF1-rep1 (2.5 µM), pre-incubated or 
not with CpOGA (5 µM), was combined with 
wild type OGT or Arg284Pro-OGT (1 µM) in 
the presence of 1 mM UDP-GlcNAc. Reaction 
mixtures were incubated at 37 ˚C for 8 h with 
gentle agitation, followed by optional addition of 
CpOGA. Mixtures were incubated at 37 ˚C for 
an additional 1 h, before stopping the reaction by 
addition of LDS loading buffer (4X) (Thermo 
Fisher Scientific). Proteins were resolved by 
SDS-PAGE (4-12% acrylamide [Life 
Technologies]) and transferred onto 
nitrocellulose membranes (GE Healthcare). 
Initial velocity for OGT-catalysed proteolysis of 
HCF1-rep1 was measured in triplicate. HCF1-
rep1 (1.5 µM) was combined with wild type 
OGT or Arg284Pro-OGT (0.15 µM) in the 
presence of 150 µM UDP-GlcNAc. Reaction 
mixtures were incubated at 37 ˚C with gentle 
agitation, while aliquots were taken out at 
designated time-points (0, 0.5, 1, 2, 4, 8, 16 and 
32 h) and stopped by mixing with LDS loading 
buffer (4X) (Thermo Fisher Scientific). The 
initial volume of the reaction was 90 µl and 2.5 
µl aliquots were loaded in each lane. Proteins 
were resolved by SDS-PAGE (10% acrylamide), 
visualized by Coomassie staining. Amount of 
product formed was quantified using a LI-COR 
Odyssey scanner and associated quantification 
software. Data was background corrected and 
plotted using GraphPad Prism 5.0.  
 
Immunoblots 
Membranes were probed with following primary 
antibodies: O-GlcNAc (RL2 [Abcam, 
Cambridge, UK]), actin (Sigma), OGT (H300 
[Santa Cruz, TX, USA]), OGA (14711-1-AP 
[Proteintech, IL, USA]), tubulin (Cell 
Signalling), HSP-90 (Cell Signalling, MA, USA) 
and GST-S902 (DSTT). In case of the far 
Western method, membranes were probed with 
10 µg/ml Halo-tagged CpOGA. and incubated 
with halo primary antibody (Promega). 
Subsequently all membranes were incubated 
with IR680- or IR800-labelled secondary 
antibodies (LI-COR) and analysed using a LI-
COR Odyssey scanner and associated 
quantification software. All primary and 
secondary antibodies were used in 1:5,000 and 
1:10,000 dilutions respectively.  
 
 
Data analysis 
Scatter plots indicate ratios of any given 
normalised signal as averaged from three 
biological replicates, with the error bars 
representing standard deviation. Variation in data 
was calculated by Mann-Whitney U test using 
Graphpad Prism 5.0. Power calculations were 
performed using G*Power 3.1.  
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TABLES 
 
Table 1: Comparison of clinical features of patients with hemizygote OGT mutations 
 
 
    Patient 1 Patient 2 
Niranjan et al, 
2015 
Bouazzi et al, 
2015 
Genotype           
Genomic change (ChrX, GRCh38) 71,555,312G>C 71,544,561T>G 71,555,223G>T 71,555,984G>A 
cDNA (NM_181672.2) 851 G>C 463-6 T>G 762 G>T 955 G>A 
Protein 
 
Arg284Pro  
 
Leu254Phe  Ala319Thr  
Phenotype           
Neurological Features 
    
 
Intellectual disability + + + + 
 
Developmental delay + + ND + 
 
Psychomotor retardation + + ND + 
 
Behavioral problems + - ND + 
Brain abnormalities + - ND - 
Cardiac symptoms + + ND - 
Dysmorphic features + + ND + 
Eye abnormalities + + ND + 
Genital/reproductive abnormalities + + ND - 
 
 
 
 
Table 2: Prediction of pathogenicity of de novo mutations detected in patient 1 
     BRD1 p.Val230Leu OGT p.Arg284Pro 
Align GVGD Class C0 Class C35 
SIFT Tolerated (score 0.06) Deleterious (score 0.01) 
MutationTaster Disease causing  (p-value: 1) Disease causing  (p-value: 1) 
Polyphen-2 Possibly damaging (score: 0.544) Probably damaging (score: 0.961) 
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FIGURES 
 
 
 
Fig. 1: Clinical images from patients with hemizygous OGT mutations 
A. Picture of patient 1, showing dysmorphic features. 
B. Pictures of patient 2, showing dysmorphic features. 
C. MRI image of patient 1, showing mild abnormalities pointing towards periventricular 
leukomalacia, indicated by red arrowheads. 
D. MRI image of patient 2, showing no brain abnormalities. 
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Fig. 2: Genetic analysis of hemizygous OGT mutations detected in patients with intellectual disability 
syndrome   
A. Location of known and newly discovered genetic variants in the OGT gene, and their 
presence in families 1 and 2. 
B. RT-PCR in skin-derived fibroblasts from patient 2 bearing the c.463-6T>G mutation 
confirmed by sequence analysis. 
C. Domain organization in human O-GlcNAc transferase. TPRs: tetratricopeptide repeats; 
TLR: tetratricopeptide-like repeat. 
D. Model for the full-length human O-GlcNAc transferase generated by superposition of 
crystallographic models for the human O-GlcNAc transferase catalytic domain (PDB: 
5V1D) and tetratricopeptide repeat domain (PDB: 1W3B). Blue colour represents 
tetratricopeptide repeats, yellow colour represents tetratricopeptide-like repeat, pink colour 
represents catalytic core. 
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Fig. 3. Characterization of global O-GlcNAc levels in patient-derived skin fibroblasts  
A. Immunoblot showing global O-GlcNAc levels in patient-derived fibroblasts detected using 
RL2 anti O-GlcNAc antibody. C: control; P: patient.  
B. The scatter plot indicates fractional ratio of any given actin-normalized signal averaged 
from three biological replicates, with the error bars representing the standard deviation. C: 
control; P: patient. p-values (Mann-Whitney U test): C1-P1 = 0.4; C1-P2 = 0.1; C2-P1 = 
0.4; C2-P2 = 0.9. Achieved power (1- error probability) = 0.1 
C. Immunoblot showing global O-GlcNAc levels in patient-derived fibroblasts detected using 
the far Western method. C: control; P: patient. The far Western method relies on detection 
of O-GlcNAcylated protein using a point mutant of a Halo-tagged bacterial O-GlcNAcase 
homolog, CpOGA
D298N
, as a probe (32). Halo antibody was used to detect the bands where 
the probe was localised. 
D. The scatter plot indicates fractional ratio of any given actin-normalized signal averaged 
from three biological replicates, with the error bars representing the standard deviation. C: 
control; P: patient. p-values (Mann-Whitney U test): C1-P1 = 0.9; C1-P2 = 0.7; C2-P1 = 
0.7; C2-P2 = 0.9. Achieved power (1- error probability) = 0.1 
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Fig. 4. Characterization of OGT and OGA levels in patient-derived skin fibroblasts 
A. Gene expression of OGT and OGA in patient fibroblasts measured by qPCR. Scatter plots 
represent mean data from two independent experiments. Gene expression was calculated 
according to ΔΔC(t) method. Tubulin expression was used as reference, and data were 
normalized against Control 1 
B. Immunoblot showing O-GlcNAc transferase (OGT) levels in patient-derived fibroblasts. 
C: control; P: patient. 
C. The scatter plot indicates fractional ratio of any given tubulin-normalized signal averaged 
from three biological replicates, with the error bars representing the standard deviation. C: 
control; P: patient. p-values (Mann-Whitney U test): C1-P1 = 0.9; C1-P2 = 0.1; C2-P1 = 
0.9; C2-P2 = 0.7. Achieved power (1- error probability) = 0.1 
D. Immunoblot showing O-GlcNAcase (OGA) levels in patient-derived fibroblasts. C: 
control; P: patient.  
E. The scatter plot indicates fractional ratio of any given tubulin-normalized signal averaged 
from three biological replicates, with the error bars representing the standard deviation. C: 
control; P: patient. p-values (Mann-Whitney U test): C1-P1 = 0.2; C1-P2 = 0.2; C2-P1 = 
0.2; C2-P2 = 0.2. Achieved power (1- error probability) = 0.1 
F. Immunoblot comparing OGT protein molecular weight, as present in fibroblasts of patient 
2 (Δ155-177) and of recombinantly expressed wild type OGT (W) and Δ155-177-OGT 
(Δ).  
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Fig. 5. In vitro analysis of recombinantly expressed mutant OGT forms 
A. Thermal denaturing curve showing fraction of unfolded wild type (TPR-WT), Arg284Pro 
(TPR-R284P) and Δ155-177 (TPR-Δ155-177) OGT  TPR domains as a function of time. 
Data were fitted to Boltzmann sigmoidal curve equation. Error bars represent standard 
error of mean of seven replicates and the plot is representative of three biological 
replicates. 
B. Immunoblot showing the relative O-GlcNAcylation activities of wild type OGT (W) and 
Arg284Pro-OGT (R) against de-O-GlcNAcylated HEK-293 lysate.  
C. Domain organization of human host cell factor 1 (HCF1) compared to its truncated form 
fused to N-terminal GST-tag and C-terminal His-tag (HCF1-rep1), which was used as a 
substrate for OGT proteolytic activity.  
D. Immunoblot showing the relative proteolytic activities of wild type OGT (W) and 
Arg284Pro-OGT (R) against HCF1-rep1. The samples were treated with an O-GlcNAcase 
homologue from Clostridium perfringens (CpOGA) either towards the end of the reaction 
(+) or from the beginning (++). Closed circle: unprocessed HCF-1rep1; Closed square: 
HCF1-rep1 cleavage product.  
E. Kinetic assay of the proteolytic activity of wild type OGT and Arg284Pro-OGT against 
HCF1-rep1 plotted as amount of product formed as a function of time. Error bars represent 
standard error of mean of four replicates. Data were fitted to hyperbolic curve equation.  
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